Cargando…

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review

BACKGROUND: It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamlagain, Rajan, Shah, Sangam, Sharma Paudel, Basanta, Dhital, Roman, Kandel, Bipin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556127/
https://www.ncbi.nlm.nih.gov/pubmed/34721573
http://dx.doi.org/10.1155/2021/8903435
_version_ 1784592120639651840
author Chamlagain, Rajan
Shah, Sangam
Sharma Paudel, Basanta
Dhital, Roman
Kandel, Bipin
author_facet Chamlagain, Rajan
Shah, Sangam
Sharma Paudel, Basanta
Dhital, Roman
Kandel, Bipin
author_sort Chamlagain, Rajan
collection PubMed
description BACKGROUND: It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role of sarilumab in the treatment of COVID-19 through this review. Main Body. Functional outcomes were assessed on the basis of PaO(2)/FiO(2) ratio, mortality, and ventilation. Adverse events of studies were also noted. Five studies were included in the study. There was improvement in PaO(2)/FiO(2) ratio, reduction in the mortality of the patients, and less number of patients were on ventilation, but there were no significant differences among the comparison and sarilumab group. Sarilumab did not have notable adverse events and can be considered a safe drug. CONCLUSION: Sarilumab is a safe drug with good clinical outcomes in patients with COVID-19 and, hence, could be used as an alternative regimen for the treatment. Further prospective studies exploring the relations with baseline biomarkers of inflammation commonly measured such as C-reactive protein and IL-6 would be necessary for a correlation with the treatment.
format Online
Article
Text
id pubmed-8556127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85561272021-10-30 Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review Chamlagain, Rajan Shah, Sangam Sharma Paudel, Basanta Dhital, Roman Kandel, Bipin Interdiscip Perspect Infect Dis Review Article BACKGROUND: It has been found that there is overactivation of immune response in patients with COVID-19. Several studies are going on to assess the role of immunomodulation. IL-6 antibodies such as tocilizumab have been found to have efficacy in the treatment of COVID-19. We aim to assess the role of sarilumab in the treatment of COVID-19 through this review. Main Body. Functional outcomes were assessed on the basis of PaO(2)/FiO(2) ratio, mortality, and ventilation. Adverse events of studies were also noted. Five studies were included in the study. There was improvement in PaO(2)/FiO(2) ratio, reduction in the mortality of the patients, and less number of patients were on ventilation, but there were no significant differences among the comparison and sarilumab group. Sarilumab did not have notable adverse events and can be considered a safe drug. CONCLUSION: Sarilumab is a safe drug with good clinical outcomes in patients with COVID-19 and, hence, could be used as an alternative regimen for the treatment. Further prospective studies exploring the relations with baseline biomarkers of inflammation commonly measured such as C-reactive protein and IL-6 would be necessary for a correlation with the treatment. Hindawi 2021-10-22 /pmc/articles/PMC8556127/ /pubmed/34721573 http://dx.doi.org/10.1155/2021/8903435 Text en Copyright © 2021 Rajan Chamlagain et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Chamlagain, Rajan
Shah, Sangam
Sharma Paudel, Basanta
Dhital, Roman
Kandel, Bipin
Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title_full Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title_fullStr Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title_full_unstemmed Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title_short Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
title_sort efficacy and safety of sarilumab in covid-19: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556127/
https://www.ncbi.nlm.nih.gov/pubmed/34721573
http://dx.doi.org/10.1155/2021/8903435
work_keys_str_mv AT chamlagainrajan efficacyandsafetyofsarilumabincovid19asystematicreview
AT shahsangam efficacyandsafetyofsarilumabincovid19asystematicreview
AT sharmapaudelbasanta efficacyandsafetyofsarilumabincovid19asystematicreview
AT dhitalroman efficacyandsafetyofsarilumabincovid19asystematicreview
AT kandelbipin efficacyandsafetyofsarilumabincovid19asystematicreview